New targeted drugs on the market by developing a database of small inhibitor molecules

We see the main value of our work in significantly accelerating the launch of new targeted drugs on the market by developing a database of small inhibitor molecules that are highly selective for pathological proteins and peptides in various diseases.
Ethical principles.

Our company deals with three areas: Alzheimer's disease, breast cancer, bone metastasis.

Our goal is to create an adaptive database of pathological proteins that take part in cascading biochemical reactions, leading to various diseases, indicating their active centers, as well as the physical parameters of their inhibitors, binding sites, affinity, key amino acid residues, three-dimensional maps of energy interactions.

 Donate | World Cancer Research Fund International
Moreover, we want to share our method and teach people how to use methods by other laboratories around the world, as this will significantly accelerate the development of drugs against other diseases. Take the development of targeted drugs to a new level in the field of exact biochemistry.

Thus, targeted inhibitors of pathological proteins are first developed using our method, and the greatest efficacy is already being tested. You no longer need to synthesize 100 molecules / antibodies, in the hope that at least one molecule has the desired biochemical properties. You can contact us and reduce a lot of fail molecules in experiments for searching new molecules.

At the moment, not a single company in the world has a methodology that would allow, within a couple of years, to select a wide range of inhibitors for all the desired pathological chemical reactions in the body, each of which is responsible for the development of a particular disease. We have ambitious tasks that require painstaking hard work. For each stage of database development, approximately 2 years are required, taking into account funding.
The faster we can collect the necessary funding, the faster we can start and finish our goals, create and register a database of pathological inhibitors of cascading pathways of biochemical reactions leading to cancer or to Alzheimer's disease.

Advantages of ordering with us

Cost evaluation of antibody production, antibody based techniques, cost effective
Cost savings
Ordering work with us, you save almost 90% on preliminary screening experiments to find the most suitable immunoglobulins
 Industrialization of mAb production technology, Monoclonal Antibody (MAb) Manufacturing,cost-effective delivery of future antibody candidates,
Three-dimensional map of the energy interaction of the amino acid sequences of an antibody with an antigen
Cost Effectiveness of Monoclonal Antibody Therapy, development has significant cost saving benefits,Development of Antibody-Based Therapeutics
No experiment needed
Determination of the affinity range for various substitutions of amino acid residues, during the formation of an antibody-antigen complex before an in vitro experiment
Current Trends in Monoclonal Antibody Development, antibodies are expected to be expensive, cost-effectiveness analysis is necessary to assess
Wide coverage
You do not have to be limited to a narrow list of substitutions of amino acid residues; instead, you get a wide range of possible modifications
cost reduction, monoclonal antibodies (mAbs) , Cost reduction can be achieved, monoclonal antibodies or recombinant proteins
Affinity range antibodies-antigen
The results obtained will determine the key amino acid residues that make the greatest changes in the affinity of the dimeric complex.
We take care about our clients time. Just contact us — and we will help you with all the questions.
Made on